亚胺培南西司他丁联合呼吸喹诺酮类药物治疗重症加强护理病房重症肺炎的临床疗效与安全性
Clinical Efficacy and Safety of Imipenem and Cilastatin combined with Respiratory Quinolones in the Treatment of Severe Pneumonia in Intensive Care Unit
常越 1王金平2
作者信息
- 1. 深圳市宝安区中心医院药剂科,广东 深圳 518000
- 2. 深圳市第二人民医院药学部,广东 深圳 518000
- 折叠
摘要
目的 比较亚胺培南西司他丁联合左氧氟沙星与亚胺培南西司他丁联合莫西沙星两种抗感染方案治疗重症加强护理病房(ICU)重症肺炎的临床疗效与安全性.方法 选取 2021 年 10 月至 2022 年 10 月深圳市宝安区中心医院ICU收治的 80 例重症肺炎患者作为研究对象,按随机数字表法分为观察组与对照组,各 40 例.在常规治疗基础上,观察组采用亚胺培南西司他丁联合左氧氟沙星治疗,对照组予以亚胺培南西司他丁联合莫西沙星,比较两组治疗效果.结果 观察组治疗有效率优于对照组(P＜0.05);治疗后,两组白细胞计数(WBC)、降钙素原(PCT)、C 反应蛋白(CRP)水平降低,且观察组低于对照组,差异有统计学意义(P＜0.05);观察组不良反应发生率与对照组比较,差异无统计学意义(P＞0.05).结论 ICU 重症肺炎患者采用亚胺培南西司他丁联合左氧氟沙星治疗,对病情早期控制、炎症指标改善、疗效提升等有积极意义,且安全性较高.
Abstract
Objective To compare the clinical efficacy and safety of imipenem cilastatin combined with levofloxacin and imipenem cilastatin combined with moxifloxacin in the treatment of severe pneumonia in intensive care unit(ICU).Methods A total of 80 patients with severe pneumonia admitted to the ICU of Shenzhen Bao'an District Central Hospital from October 2021 to October 2022 were selected as the study objects,and were divided into observation group and control group according to random number table method,with 40 cases in each group.On the basis of conventional treatment,the observation group was treated with imipenem cilastatin combined with levofloxacin,and the control group was treated with imipenem cilastatin combined with moxifloxacin.The therapeutic effect of the two groups was compared.Results The effective rate of observation group was better than control group(P＜0.05).After treatment,the levels of WBC,PCT and CRP in the two groups were decreased,and the observation group was lower than the control group,the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P＞0.05).Conclusion The combination of imipenem and cilastatin with levofloxacin in ICU patients with severe pneumonia has positive significance in early disease control,improvement of inflammatory indicators,and improvement of curative effect,with high safety.
关键词
亚胺培南西司他丁/左氧氟沙星/莫西沙星/重症肺炎Key words
Imipenem cilastatin/Levofloxacin/Moxifloxacin/Severe pneumonia引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据